A California jury's decision on Tuesday may result in Gilead Sciences losing billions of dollars, as claims from pharmaceutical company Merck that the California-based company's blockbuster drug's active ingredients infringed its patents were found valid in the court.
Gilead's new CEO told CNBC, however, that this isn't the end of the dispute. "We still think the Merck patents are invalid and we continue to believe that we have a strong case for that, and we do plan to appeal the case at the end of the day," John Milligan told CNBC on Wednesday.
While the drugmaker's Hepatitis C franchise has driven Gilead's business upward, it's drug-pricing practices have received backlash recently since combination drug Harvoni costs $1,125 per pill before discounts, and a 12-week regimen costs $94,000.
Drug-pricing disputes aren't all that rare these days. Pharma bad boy Martin Shkreli's raising the price of antiparasitic drug Daraprim from $13.50 per pill to $750 per pill, garnered a lot of attention and public concern, recently.